Cadila Healthcare gets FDA marketing OK for anti-nausea drug Promethazine

By Angela McDaniels

Seattle, Nov. 21 - Cadila Healthcare Ltd. said it has received approval from the U.S. Food and Drug Administration to market Promethazine 12.5 mg, 25 mg and 50 mg tablets as a treatment for nausea and vomiting.

Cadila, a pharmaceutical company based in Ahmedabad, India, plans to launch the drug this year.

U.S. sales of Promethazine reach $116 million annually, the company said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.